Tuesday 7 November Friday 10 November 2006 Prague, Czech Republic

[Prague Congress Centre, 5 kvetna 65, CZ-140 21 Prague 4]

There are just three weeks to go to this joint European Organisation for Research and Treatment of Cancer, US National Cancer Institute and American Association for Cancer Research conference.

It offers:

• Cutting edge information on new cancer drug research and development from experts in Europe, North America, Asia and Australia.

• Free registration to bona fide media with official press credentials

• Media centre with free computing, fax, international phone and internet facilities

• Two news briefings [12.30 hrs CET: Wednesday 8 November & Thursday 9 November]

Topics at the news briefing or to be press-released include:

• MEK inhibitor produces stable disease in advanced solid cancers; phase II trials started

• Drug that interrupts a key stage of cell division shows promise in patients with solid tumours

• New evidence that embryonic stem cell vaccinations prevent lung cancer in mice this raises the possibility of preventing a range of cancers in humans

• Scientists discover new way to block growth of prostate cancer cells; patient trials planned

• Remarkable results from treating kidney cancer patients before surgery with bevacizumab and erlotinib

• Researchers identify cells that make relapse inevitable after treatment for acute lymphoblastic leukaemia now new therapies can be designed to target these cells

• Diptheria toxin used in new immunotherapy against melanoma in humans; promising results from phase II trial

• Scientists design a PSA-activated drug that kills prostate cancer. It has potential for treating men with locally recurrent or advanced disease, or with benign prostatic hyperplasia phase I trial now un
  '"/>